Quince Therapeutics, Inc. (QNCX): EBITDA
-$57.93M
Year ended 2025-12-31
-$127.00M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$57.93M | n/m | 2026-04-10, From 2025-01-01 |
| 2024-12-31 | -$57.10M | n/m | 2026-04-10, From 2024-01-01 |
| 2023-12-31 | -$34.30M | n/m | 2025-03-24, From 2023-01-01 |
| 2022-12-31 | -$51.81M | n/m | 2024-04-01, From 2022-01-01 |
| 2021-12-31 | -$89.97M | n/m | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | -$78.56M | n/m | 2022-03-01, From 2020-01-01 |
| 2019-12-31 | -$38.98M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | -$12.07M | n/a | 2021-03-01, From 2018-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | 2025-12-31 | -$57.93M | n/m |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | -$76.96M | n/m |
| Surrozen, Inc. (SRZN) | 2025-12-31 | -$41.55M | n/m |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | -$22.60M | n/m |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | -$35.92M | n/m |
| Armata Pharmaceuticals, Inc. (ARMP) | 2024-12-31 | -$41.11M | n/m |
| Zura Bio Ltd (ZURA) | 2025-12-31 | -$75.20M | n/m |
| Artiva Biotherapeutics, Inc. (ARTV) | 2025-12-31 | -$87.21M | n/m |
| Elutia Inc. (ELUT) | 2025-12-31 | -$24.13M | n/m |
Compare QNCX, ATYR, SRZN, ACOG side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗